Navigation Links
Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
Date:8/6/2009

REDWOOD CITY, Calif.,, Aug. 6 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the publication in Cell Stem Cell of data demonstrating potent anti-cancer activity in colon and breast cancer models for the company's first product candidate, OMP-21M18, underlining the therapeutic potential of targeting cancer stem cells to treat solid tumors. OMP-21M18 is currently in Phase 1 clinical testing.

"OMP-21M18 specifically targets cancer stem cells, a type of tumor cell responsible for driving tumor initiation, growth and recurrence. Research published in Cell Stem Cell suggests that reducing the ratio of these cells within tumors may dramatically improve anti-cancer treatment," said Timothy Hoey, Ph.D., Vice President, Cancer Biology of OncoMed Pharmaceuticals and a co-author of the paper. "In models of colon and breast cancer, we observed that treatment with OMP-21M18 significantly decreased the proportion of cancer stem cells found in tumors compared to chemotherapy alone. In addition, we demonstrated that blocking a key cancer stem cell pathway impacts tumor cell proliferation, growth and recurrence."

OMP-21M18 is a monoclonal antibody that blocks DLL4 signaling to reduce tumor growth two ways: by reducing cancer stem cell frequency and by disrupting angiogenesis. In a series of published experiments using primary human tumors in xenograft models, OncoMed scientists assessed the effect of OMP-21M18 alone and in combination with approved chemotherapeutic agents versus chemotherapy alone on the frequency of cancer stem cells in treated tumors. Results demonstrate that treatment with OMP-21M18 as a single agent or in combination with standard chemotherapeutic agents significantly decreases the ratio of cancer stem cells found in colon and breast tumors. Notably, treat
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
3. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
4. Vasogens Research Published in European Journal of Neuroscience
5. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
6. Newly Published EPA RCRA Method 6800 Supports AIT Technology
7. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
8. WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy
9. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
10. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
11. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...-TwomoreprestigiousuniversitieshavejoinedBioCareer...iteforlifescienceprofessionals. ,, Northwestern...ining28othermajorlifesciencetrainingInstitutions. ...forpost-graduatesinthelifesciences.Whiletherearehu...eerCenteristheonlyonethatserveslifesciencepost-gra...
(Date:11/24/2009)...ire-FirstCall/--deCODE,genetics,Inc.(Nasdaq: DCGN ...ionsbytheU.S.BankruptcyCourtfortheDistrictofDelawa...ntarypetitionfor,reliefunderChapter11oftheUnitedSt...TheordersissuedbytheBankruptcyCourtallowthecompany...roceedings.Inparticular,the,companyreceivedinterim...
(Date:11/24/2009)...pproved the Promega PowerPlex 16 HS System for use...A records for the National DNA Index System. , ...he FBI recently approved the Promega PowerPlex&re...ting in, or generating DNA records for, the Nation...s more than seven million profiles and has assiste...
(Date:11/24/2009)...-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX )toda...hairman,willpresentatthe21stAnnualPiperJaffrayHeal...009at10:00a.m.ET. ,, Toaccesstheliveandsubseque...torRelationssectionofGenomicHealth,swebsiteat http...ebsiteatleast15minutespriortothebeginningofthepres...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Genomic Health to Present at Piper Jaffray Health Care Conference 2
..., Calif., May 28 CV Therapeutics,Inc. (Nasdaq: C...daq,marketplace rule 4350, the Company issued new ...ers due to additional hiring, primarily in connect...ed States., The inducement stock options cover an...classified as non-qualified stock options with an,...
...Genmab Reports Results for the First Three Months ...N),announced today results for the three month per...ab reported the following results:, Genmab,s reve... for the,first quarter of 2008. In the same period...lion (approx. USD 17 million)., An operating loss...
...hio, May 28 The automation of,transaction-based p...alth,plans in the United States. Foresight Corpora...mber and scale of installations of Transaction,Ins...n automation., Transaction automation techniques ... costs significantly by integrating validation, er...
Other Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2Genmab Announces 2008 First Quarter Results 2Genmab Announces 2008 First Quarter Results 3Genmab Announces 2008 First Quarter Results 4New Trend Sweeping Nation's Health Plans: Transaction Automation 2
(Date:11/23/2009)...urrent research suggests that a common oral bacter...d report by Nichols et al, "Unique Lipids from a C...2 Ligands Capable of Enhancing Autoimmunity," appe...urnal of Pathology . , Multiple sclerosis (MS), ...n and spinal cord, affects nearly 1 in 700 people ...
(Date:11/23/2009)... - By producing some of the highest resolution ima...entists have a deeper understanding how biomolecul...ay lead to a new treatment for kidney stones using...the Nov. 23 online edition of the journal Proceed...s how peptides interact with mineral surfaces by a...
(Date:11/23/2009)...niversity of New Hampshire microbiologist Louis Ti...vance understanding of the actinorhizal plants, wi...rient-poor and contaminated soils. , The United...isa, a professor of molecular, cellular and biomed...elationship between the bacteria Frankia and Casua...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3UNH prof. receives nearly $500,000 to research environmentally significant plants 2Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 54344 1Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 54344 2Scientists Reverse Multiple Sclerosis in Mice 54342 1Scientists Reverse Multiple Sclerosis in Mice 54342 2Human mind 3A Sound and vision wired through same black box 54340 1Human mind 3A Sound and vision wired through same black box 54340 2
...ies are repairing the human body in ways never ima...n increasing population of patients who are newly ...nd chronic fungal infections have become a formida... Aspergillus fumigatus , the focus of a new text f... engineered to offer the latest insights into the ...
...le in Spanish . , , The conditioning Works of S...unt of vegetable species. The researchers of the ...d to grow in the laboratory two native bushy speci...e cover restoration. They will try to use them to ... Sierra Nevada . , The vegetable species of Sierr...
...ke Salmonella typhimurium employ a startling arr...efense mechanisms and produce illness. Through th...ocks of cellular physiologysuch microbes ingenious...isease-causing potential or virulence. , Althou...ce factors is now well advanced, many pieces of th...
Other Biology News:New text focuses on formidable opportunistic fungus 2An essay proves that vegetation could recover in the ski resort of Sierra Nevada 2The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 2The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 3The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 4The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 5
...throughput protein crystallography involves using ...ut Screening (HTS). The liquid handling requiremen...itional crystallography plates have 24 or 48 wells...her throughput, the number of wells has increased ...
...everse-iT™ One-Step Kit is the ultimate in co...CR. It has been specifically designed to streamlin...ep Kit combines the unique Reverse-iT™ Blend ...olymerase to provide a highly sensitive, reproduci...
...nogen: Synthetic Peptide: M(1) E F L P E P Q H P ...racting protein 3 (Mint3) from mouse cells.,P...procedures. By Western blot, this antibody detect... cell extract.,PA1-072 immunizing peptide cor...
Custom LNA Oligonucleotide synthesis from Exiqon
Biology Products: